Tissue Regenix Group plc
TRX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £28 | £53 | £58 | £47 |
| - Cash | £1 | £2 | £3 | £5 |
| + Debt | £11 | £10 | £10 | £9 |
| Enterprise Value | £38 | £62 | £65 | £51 |
| Revenue | £14 | – | £13 | £5 |
| % Growth | – | – | 186.9% | – |
| Gross Profit | £6 | – | £7 | £2 |
| % Margin | 41.8% | – | 52.5% | 55.3% |
| EBITDA | £0 | – | £1 | £0 |
| % Margin | 0% | – | 6.4% | 5.2% |
| Net Income | -£1 | – | -£0 | -£1 |
| % Margin | -6.8% | – | -1.7% | -14.2% |
| EPS Diluted | -0.014 | – | -0.003 | -0.009 |
| % Growth | – | – | 65.9% | – |
| Operating Cash Flow | -£0 | £0 | -£1 | £1 |
| Capital Expenditures | -£0 | £0 | -£0 | -£0 |
| Free Cash Flow | -£0 | £0 | -£2 | £1 |